|
⚲
|
| Gloucester Pharmaceuticals Inc | |
|---|---|
| Firm | |
| Fund # | |
| CIK # | 0001307826 |
| Sale | 2009-08-14 ($28.9 M Offered, $20.3 M Sold) |
| Fund | |
| Phone | 6175831300 |
| Address | 1 Broadway Cambridge, 02142 |
| Source | [EDGAR] |
| Fund AUM and Sold ($M) |
|---|
| Fund Details | |
|---|---|
| Director | |
| Custodian | |
| Auditor | |
| Marketer | |
| Broker | |
| Jurisdiction |
| Directors | 2011 - 2025 |
|---|---|
| Seth Harrison | |
| Martin Vogelbaum | |
| Jean Nichols | |
| Alan Colowick | |
| Jay Moorin | |
| David Schnell | |
| Nicholas Vrolijk | |
| Donald Hayden | |
| Thomas Dyrberg |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
Legacy K, LLC
✚
|
0.0 | |
|
Legacy P3 LLC
✚
|
0.0 | |
|
Legacy Rylan SWD 1 LLC
✚
|
0.0 | |
|
Legacy Venture X, LLC
✚
|
0.0 | |
|
Legal & General MSCI EAFE SL Fund LLC
✚
|
0.0 | |
|
Legal & General S&P 400 SL Fund LLC
✚
|
0.0 | |
|
Legal & General S&P 600 SL Fund LLC
✚
|
0.0 | |
|
Legal Sifter, Inc.
✚
|
0.0 | |
|
Legion Partners Special Opportunities, L.P. XIV
✚
|
0.0 | |
|
Legacy Growth Fund, LLC
✚
|
0.0 |